Handelsbanken Fonder’s BioCryst Pharmaceuticals BCRX Stock Holding History

Handelsbanken Fonder’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-45,900	Closed	-$233K	–	1529
2024 Q1	$233K	Hold	45,900	–	–	﹤0.01%	1461
2023 Q4	$275K	Buy	45,900 +10,400	+29%	+$60.3K	﹤0.01%	1407
2023 Q3	$251K	Hold	35,500	–	–	﹤0.01%	1374
2023 Q2	$250K	Hold	35,500	–	–	﹤0.01%	1416
2023 Q1	$296K	Hold	35,500	–	–	﹤0.01%	1295
2022 Q4	$408K	Buy	35,500 +8,400	+31%	+$105K	﹤0.01%	1067
2022 Q3	$341K	Sell	27,100 -8,600	-24%	-$111K	﹤0.01%	1172
2022 Q2	$378K	Hold	35,700	–	–	﹤0.01%	1186
2022 Q1	$580K	Sell	35,700 -11,400	-24%	-$183K	﹤0.01%	1092
2021 Q4	$652K	Sell	47,100 -18,600	-28%	-$246K	﹤0.01%	1166
2021 Q3	$944K	Buy	65,700 +6,200	+10%	+$97.8K	﹤0.01%	937
2021 Q2	$941K	Buy	+59,500	New	+$808K	﹤0.01%	959

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Handelsbanken Fonder's BCRX Position: Q2 2024 in Review

Handelsbanken Fonder sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2024, closing a stake of 45,900 shares — an estimated $233K sold.

Handelsbanken Fonder first reported a position in BCRX in Q2 2021 and held it in 12 quarters. The position peaked at $944K in Q3 2021. 241 funds tracked by Wall St. Rank hold BCRX as of Q2 2024.

Handelsbanken Fonder reported no remaining BioCryst Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Handelsbanken Fonder sold 45,900 BioCryst Pharmaceuticals shares in Q2 2024, an estimated $233K.
Handelsbanken Fonder first reported a position in BioCryst Pharmaceuticals in Q2 2021 and held it in 12 quarters.
Handelsbanken Fonder's BioCryst Pharmaceuticals position peaked at $944K in Q3 2021.
241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2024.

Based on Handelsbanken Fonder's 13F filing for Q2 2024, filed 5 Aug 2024.